Aetna Wun Trombley, President and CEO of Lycia Therapeutics, Inc., filed a Form 4 on October 26, 2026, disclosing the acquisition of stock options granted on August 11, 2026, prior to the company's initial public offering.

Key Highlights

  • Reporting person: Aetna Wun Trombley, identified as President and CEO, Director, and 10% Owner of Lycia Therapeutics, Inc. (NASDAQ:LYCA).
  • Transaction date: August 11, 2026, with the filing submitted October 26, 2026.
  • Options granted: 443,586 stock options (right to buy) with an exercise price of $3.70 per share, acquired at a price of $0.
  • Underlying security: Common Stock, with 443,586 shares underlying the options.
  • Vesting schedule: Options vest 1/48 of the total award monthly over four years, with the first tranche vested on September 6, 2026, subject to continued service.
  • Expiration date: August 10, 2036.
  • Pre-IPO transaction: According to the filing, the transaction occurred prior to the issuer's registration of a class of equity securities under Section 12 of the Exchange Act in connection with the issuer's initial public offering, and is reported pursuant to Rule 16a-2(a).

Trombley Option Grant at Lycia Therapeutics: Pre-IPO Award Details

According to the Form 4 filed with the SEC on October 26, 2026, Aetna Wun Trombley, who serves as President, CEO, Director, and 10% Owner of Lycia Therapeutics, Inc. (NASDAQ:LYCA), reported the acquisition of 443,586 stock options. The options carry an exercise price of $3.70 and were acquired at a price of $0, with the transaction dated August 11, 2026. The filing notes that this transaction occurred prior to the issuer's registration of a class of equity securities under Section 12 of the Exchange Act in connection with the issuer's initial public offering, and is being reported pursuant to Rule 16a-2(a).

The filing discloses that the options vest as to 1/48 of the total award monthly over four years, with the first tranche having vested on September 6, 2026, subject to the reporting person's provision of service to the issuer on each vesting date. The underlying security is Common Stock, with 443,586 shares underlying the derivative. The options are held directly and are set to expire on August 10, 2036. Following this transaction, the filing reports that Trombley beneficially owns 443,586 derivative securities.

The Form 4 was signed by Amy Bachrodt as Attorney-in-Fact on October 26, 2026. No transactions were reported in Table I covering non-derivative securities. The filing was made by one reporting person. Lycia Therapeutics, Inc. is located at 400 East Jamie Court, Suite 200, South San Francisco, California 94080, according to the address listed on the form.

What Was Disclosed

Lycia Therapeutics President and CEO Aetna Wun Trombley reported the acquisition of 443,586 stock options at an exercise price of $3.70, granted August 11, 2026, prior to the company's IPO, vesting monthly over four years and expiring August 10, 2036.